Central Pharmaceuticals has been growing earnings at an average annual rate of 9.4%, while the Pharmaceuticals industry saw earnings growing at 2.2% annually.
Key information
9.42%
Earnings growth rate
9.43%
EPS growth rate
Pharmaceuticals Industry Growth
11.00%
Revenue growth rate
n/a
Return on equity
-2.34%
Net Margin
-54.92%
Last Earnings Update
31 Dec 2025
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Central Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
DSE:CENTRALPHL Revenue, expenses and earnings (BDT Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Dec 25
34
-19
11
0
30 Sep 25
34
-29
12
0
30 Jun 25
33
-22
12
0
31 Dec 24
-28
-44
17
0
30 Sep 24
7
-38
17
0
30 Jun 24
30
-42
17
0
31 Mar 24
112
-59
30
0
31 Dec 23
90
-46
19
0
30 Sep 23
54
-41
18
0
30 Jun 23
29
-44
19
0
30 Sep 22
25
-68
13
0
30 Jun 22
26
-68
16
0
30 Jun 21
148
-8
22
0
30 Jun 20
140
-1,107
611
0
31 Mar 20
173
-545
325
0
31 Dec 19
206
17
39
0
30 Sep 19
234
30
41
0
30 Jun 19
307
57
45
0
31 Mar 19
355
83
42
0
30 Sep 18
371
81
54
0
30 Jun 18
320
61
54
0
31 Mar 18
272
29
56
0
30 Sep 17
473
112
62
0
30 Jun 17
456
109
60
0
31 Mar 17
485
133
62
0
31 Dec 16
440
116
62
0
30 Sep 16
348
81
59
0
30 Jun 16
417
98
68
0
31 Mar 16
477
100
85
0
31 Dec 15
553
122
89
0
30 Sep 15
624
135
93
0
30 Jun 15
661
143
94
0
Quality Earnings: CENTRALPHL is currently unprofitable.
Growing Profit Margin: CENTRALPHL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CENTRALPHL is unprofitable, but has reduced losses over the past 5 years at a rate of 9.4% per year.
Accelerating Growth: Unable to compare CENTRALPHL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CENTRALPHL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (8.6%).
Return on Equity
High ROE: CENTRALPHL has a negative Return on Equity (-2.34%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/05/28 22:37
End of Day Share Price
2026/05/24 00:00
Earnings
2025/12/31
Annual Earnings
2025/06/30
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Central Pharmaceuticals Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.